ArticleJournal of gynecologic oncology2023
Efficacy of lymph node dissection on stage IIICr of cervical cancer before CCRT: study protocol for a phase III, randomized controlled clinical trial (CQGOG0103).
Article in Journal of gynecologic oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04555226 (Randomized Controlled Trial of the Efficacy of Lymph Node Dissection on Stage IIICr of Cervical Cancer), which is not on this map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized Controlled Trial of the Efficacy of Lymph Node Dissection on Stage IIICr of Cervical Cancer
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 10 citations in OpenAlex.
- Survival Benefit of Surgical Staging Before Radiotherapy in Locally Advanced Cervical Cancer: A Pooled Analysis.Cancer science · 2025Pooled it
- Lymph node dissection before initial treatment for locally advanced cervical cancer: A systematic review and meta-analysis.Biomolecules & biomedicine · 2024Pooled it
- Primary chemoradiation versus radical hysterectomy with lymphadenectomy for stage IIICr cervical cancer without parametrial involvement: gynecologic oncology research investigators collaboration study (GORILLA-1002).Journal of gynecologic oncology · 2026Article
- Para-Aortic Lymph Node Staging and Oncologic Outcomes in Locally Advanced Cervical Cancer: A Narrative Review.Cancers · 2026Review
- Laparoscopic para-aortic and pelvic lymphadenectomy before chemoradiotherapy was not associated with improved survival in patients with FIGO stage IIB-IIIC cervical cancer: a single-center retrospective study.Frontiers in oncology · 2026Article
- Surgical Staging in Locally Advanced Cervical Cancer: Precision, Risks, and the 'Helmet' Analogy.Cancers · 2025Article
- Reliability study of MRI in detecting lymph node metastasis of cervical cancer: a multi-center retrospective study result analysis.Quantitative imaging in medicine and surgery · 2025Article
- Current Paradigm and Future Directions in the Management of Nodal Disease in Locally Advanced Cervical Cancer.Cancers · 2025Review
- Therapeutic effects of surgical debulking of metastatic lymph nodes in cervical cancer IIICr: a trial protocol for a phase III, multicenter, randomized controlled study (KGOG1047/DEBULK trial).Journal of gynecologic oncology · 2024Article
- Controversies and Advances in the Personalized Surgical Treatment of Cervical Cancer.Journal of personalized medicine · 2024Review
- Controversies in the Staging of Patients with Locally Advanced Cervical Cancer.Diagnostics (Basel, Switzerland) · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 9 institutions in 1 country.
Funding
Abstract
backgroundCervical cancer is still present a major public health problem, especially in developing countries. In International Federation of Gynaecology and Obstetrics 2018, allowing assessment of retroperitoneal lymph nodes by imaging and/or pathological findings and, if deemed metastatic, the case is designated as stage IIIC (with r and p notations). Patients with lymph node metastases have lower overall survival (OS), progression free survival (PFS), and survival after recurrence, especially those who have unresectable macroscopical positive lymph nodes. Retrospective analysis suggests that there may be a benefit to debulking macroscopic nodes that would be otherwise difficult to sterilize with standard doses of radiation therapy. However, there are no prospective study reporting that resecting macroscopic nodes before concurrent chemoradiation therapy (CCRT) would improve PFS or OS of cervical cancer and no guidelines for surgical resection of bulky lymph nodes. The CQGOG0103 study is a prospective, multicenter and randomized controlled trial (RCT) evaluating lymph node dissection on stage IIICr of cervical cancer.
methodsEligible patients are histologically confirmed cervical squamous cell carcinoma, adenocarcinoma, adeno-squamous cell carcinoma. Stage IIICr (confirmed by computed tomography [CT]/magnetic resonance imaging/positron emission tomography/CT) and the short diameter of image-positive lymph node ≥15 mm. 452 patients will be equally randomized to receive either CCRT (pelvic external-beam radiotherapy [EBRT]/extended-field EBRT + cisplatin [40 mg/m²] or carboplatin [the area under curve=2] every week for 5 cycles + brachytherapy) or open/minimally invasive pelvic and para-aortic lymph node dissection followed by CCRT. Randomization is stratified by status of para-aortic lymph node. The primary endpoint is PFS. Secondary endpoints are OS and surgical complications. A total of 452 patients will be enrolled from multiple hospitals in China within 4 years and followed up for 5 years.
trial registrationClinicalTrials.gov Identifier: NCT04555226.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.